Cell-Free Protein Synthesis — PatSnap Eureka
Cell-Free Protein Synthesis: Scalable Biologic Production Beyond the Cell
CFPS decouples protein production from cellular viability, enabling rapid, scalable synthesis of mAbs, ADCs, cytokines, and antimicrobial peptides — from microliter screening to 25,000 L commercial volumes. Explore the full IP and R&D landscape with PatSnap Eureka.
Six Pathways to Cell-Free and Non-Biological Biologic Production
From life sciences manufacturing infrastructure to next-generation RNA therapeutics, the dataset spans commercial-stage platforms through early research tools.
E. coli Open Cell-Free Synthesis (OCFS)
Sutro Biopharma's OCFS platform uses bacterial cell lysates to drive coupled transcription–translation in vitro. The 2023 patent claims antibody production at 10–25,000 L reaction volumes, with separate heavy and light chain expression to improve correctly assembled IgG yields. Chaperone supplementation (DsbC, FkpA, GroEL/ES, DnaK) enables disulfide-bonded protein folding.
Commercial / Manufacturing ScalePURE System — Fully Reconstituted Translation
The PURE (Protein synthesis Using Recombinant Elements) system uses defined, purified components. Harvard Medical School achieved up to 5-fold productivity improvements by optimizing elongation factors (EF-Ts, EF-Tu, EF-G, EF4) and chaperones. RIKEN's RF-1-deleted E. coli strains (RFzero-iy) enable non-natural amino acid (UNAA) incorporation at UAG codons with >90% translation efficiency.
Advanced Preclinical / Research ToolCHO and Wheat Germ Platforms
Imperial College London's CHO-based CFPS platform uses GADD34 and K3L accessory proteins to prevent translational machinery inactivation, achieving up to 100-fold yield improvement over baseline. Techno-economic modelling indicates CHO-CFPS requires significant yield increases to match conventional CHO manufacturing economics — a high-value technical gap for glycoprotein targets requiring eukaryotic post-translational modifications.
Yield-Limited BottleneckEngineered mRNA as a Manufacturing Bypass
Rather than synthesizing proteins ex vivo, engineered mRNA therapeutics direct the patient's own cellular machinery to produce therapeutic proteins. CureVac demonstrated sequence-engineered unmodified mRNA driving physiological EPO responses in pigs (~20 kg body weight) from a single dose. Moderna (2021) explicitly frames mRNA-encoded antibodies as addressing manufacturing and purification challenges for mAbs.
Preclinical to Early Clinical SignalsIntegrated Downstream Continuous Processing
Genzyme Corporation holds 6 active patent families (all IL jurisdiction) covering integrated continuous manufacturing of therapeutic protein drug substances using multi-column chromatography systems (MCCS1 and MCCS2). Lund University (2022) describes the first known integrated continuous bioprocess (ICB) for acid-sensitive mAbs at pilot scale, with ~90% recovery yields. UCL techno-economic modelling indicates improved cost of goods per gram (COG/g) and reduced environmental impact vs. batch processing.
Commercial / Industrial StageTotal Chemical Synthesis — Non-Biological Route
Ohio State University describes a convergent hybrid phase native chemical ligation (CHP-NCL) strategy for synthesis of 212-residue proteins from short peptide segments. A Berlin-affiliated group reports total on-resin synthesis of proteins without HPLC purification. Carnegie Mellon describes protein–polymer conjugate synthesis via ATRP on reversible immobilization supports. Evidence is academic literature only; stage is research/preclinical.
Research / PreclinicalFrom Monoclonal Antibodies to Antimicrobial Peptides: What CFPS Produces
Monoclonal antibodies (IgG, scFv, Fab formats) represent the highest-density target class across retrieved results, spanning oncology, autoimmune disease (etanercept, tocilizumab analogues), and infectious disease (MERS-CoV, HIV). Sutro Biopharma's patent (IL, 2023) describes expressing heavy chain (HC) separately from light chain (LC) to improve correctly assembled IgG yields at commercial scale.
Antibody–drug conjugates (ADCs) represent the most clinically relevant non-natural amino acid application in the dataset. Sutro Biopharma (2021) describes engineering the E. coli chromosome for continuous fermentation extract production with integrated IgG-folding chaperones (DsbC, FkpA) and orthogonal tRNA for site-specific UNAA incorporation — enabling homogeneous ADC production, a manufacturing advantage over stochastic lysine/cysteine conjugation. Learn more about IP analytics for ADC development on the PatSnap platform.
Antimicrobial peptides (AMPs) represent a frontier application: Goethe University Frankfurt (2022) reports a CFPS pipeline combined with deep learning to design and screen 500 de novo AMP candidates, identifying 30 functional AMPs including 6 with broad-spectrum activity against multidrug-resistant pathogens. This constitutes the clearest example of AI-augmented cell-free drug discovery in the dataset.
Natural products — polyketides (PKs) and nonribosomal peptides (NRPs) — are produced via CFPS-based pathway reconstruction by ShanghaiTech University, circumventing host-cell toxicity and pathway incompatibility barriers of in vivo heterologous expression. According to WHO, antimicrobial resistance is one of the greatest threats to global health, making cell-free AMP discovery pipelines particularly timely.
CFPS Manufacturing Landscape: Key Metrics Visualised
Data derived from patent filings, academic literature, and techno-economic analyses retrieved via PatSnap Eureka.
Innovation Signals by CFPS Modality
Prokaryotic E. coli-based CFPS dominates patent and literature signals, followed by mRNA in vivo production and continuous biomanufacturing.
Lyophilized CFPS Vaccine Cost Benchmarks
Cornell University (2022) demonstrated lyophilized CFPS conjugate vaccine production at $0.50/dose (room temperature) and $1.00/dose (50°C, 4 weeks) — generating bactericidal antibodies against ETEC O78 in mice.
Key Assignee Activity: Patent vs. Literature Signal Mix
Commercial patent activity is concentrated in Sutro Biopharma and Genzyme Corporation; academic literature signals span Tsinghua, Imperial College, Cornell, and RIKEN.
Six Directions Reshaping Cell-Free Biologic Manufacturing
Retrieved results signal multiple convergence strategies where CFPS intersects with AI, lyophilization, mRNA, and continuous processing to create new IP and commercial opportunities.
CFPS + Deep Learning for Drug Discovery
Goethe University Frankfurt (2022) used CFPS as a rapid, low-cost experimental validation platform for AI-designed AMP candidates, screening 500 designs and identifying 30 functional AMPs — 6 with broad-spectrum activity against multidrug-resistant pathogens. CFPS is being positioned as the experimental layer in AI-driven drug discovery pipelines, collapsing the design-build-test cycle. The WHO identifies AMR as a critical global health priority.
CFPS + Lyophilization for Decentralized Manufacturing
Cornell University (2022) and University of Toronto (2018) both describe freeze-dried CFPS systems deployable outside laboratory settings. Cornell's conjugate vaccine data (~$0.50/dose after room-temperature storage for 4 weeks) represents a concrete cost and logistics benchmark relevant to pandemic preparedness, low-income country access, and point-of-care manufacturing programs. University of Cambridge (2022) describes low-cost extract drying using silica bead-based devices as an accessible alternative to commercial lyophilizers.
mRNA + LNP as Manufacturing Bypass
Moderna, CureVac, and Suzhou CureMed Biopharma describe engineered mRNA as a mechanism to bypass recombinant protein manufacturing entirely. Clean-PIE circular RNA technology (Suzhou CureMed, 2022) and "superfolder" mRNA design principles (Stanford/Eterna, 2022) suggest next-generation RNA structures may further improve protein output and stability. Drug developers should evaluate which protein targets are better served by CFPS (large quantity, purified drug substance) versus mRNA delivery (sustained in vivo expression).
CFPS + Continuous Downstream Integration
Genzyme patents and UCL's process modelling suggest that while CFPS addresses upstream complexity, continuous chromatography platforms (MCCS1/MCCS2) provide the downstream counterpart. Sutro's chromosome-integrated continuous fermentation for extract production signals movement toward integrating both upstream extract production and reaction execution into continuous processes. PatSnap Analytics can map the IP landscape for integrated bioprocessing.
Key Assignees and Development Stage Signals
Commercial patent activity is concentrated in Sutro Biopharma and Genzyme Corporation. Academic research leaders span Tsinghua, Imperial College, Cornell, and RIKEN. Explore the full landscape with PatSnap IP Analytics.
| Assignee | Focus Area | Evidence Type | Development Stage | Key Finding |
|---|---|---|---|---|
| Sutro Biopharma, Inc. | E. coli OCFS, ADCs, Cytokines | Patents + Papers | Commercial | 10–25,000 L CFPS antibody production claimed (2023 IL patent) |
| Genzyme Corporation | Integrated continuous downstream processing | 6 Active Patents (IL) | Commercial | MCCS1/MCCS2 multi-column chromatography; GMP-consistent language |
| Moderna, Inc. | mRNA-encoded antibodies, mRNA chemistry | Academic/Commercial Papers | Preclinical–Early Clinical | mRNA-encoded mAbs framed as manufacturing bypass for difficult-to-purify formats |
| CureVac GmbH | Sequence-engineered unmodified mRNA | Academic Paper | Preclinical | Physiological EPO response in pigs (~20 kg) from single mRNA dose (2015) |
| Imperial College London | CHO-CFPS platform; techno-economic modelling | Academic Papers | Preclinical | 100× yield improvement with GADD34/K3L; CHO-CFPS requires yield gains to match CHO economics |
| Cornell University | Lyophilized CFPS for decentralized vaccine manufacturing | Academic Paper | Preclinical | ~$0.50/dose conjugate vaccine; bactericidal antibodies vs. ETEC O78 in mice (2022) |
| RIKEN Center for Biosystems Dynamics Research | RF-1-deleted E. coli for UNAA incorporation | Academic Paper | Research | RFzero-iy strains: >90% translation efficiency at UAG codons (2019) |
| Goethe University Frankfurt | CFPS + deep learning for AMP discovery; NRP biosynthesis | Academic Papers | Research | 500 AI-designed AMP candidates screened; 30 functional AMPs, 6 broad-spectrum (2022) |
Track CFPS patent filings and continuation activity in real time
PatSnap Eureka monitors 200M+ patent records across 100+ jurisdictions — set alerts for Sutro, Genzyme, and emerging CFPS assignees.
What the CFPS IP Landscape Means for R&D and IP Strategy
CFPS at commercial scale is no longer purely academic. Sutro Biopharma's 2023 patent claiming antibody production at up to 25,000 L reaction volumes and Genzyme's suite of active continuous manufacturing patents signal that the field has crossed from research tool to commercial infrastructure. IP strategists should monitor continuation patents and divisionals in this space. The European Patent Office and USPTO are both active jurisdictions for CFPS filings.
Eukaryotic CFPS remains a yield-limited bottleneck. Retrieved techno-economic data from Imperial College indicate CHO-based CFPS requires significant yield improvements to be cost-competitive with stable CHO cell culture. This represents a high-value technical gap for R&D investment, particularly for glycoprotein targets requiring eukaryotic post-translational modifications.
UNAA incorporation combined with CFPS is the enabling technology for next-generation ADCs. Sutro's chromosome-engineered E. coli strains producing orthogonal tRNA constitutively — combined with site-specific UNAA incorporation for homogeneous ADC conjugation — represent a manufacturing advantage over stochastic lysine/cysteine conjugation. This is likely to drive further IP activity around extract strain engineering and orthogonal translation machinery. Review PatSnap customer case studies for life sciences IP strategy examples.
Lyophilized CFPS for decentralized vaccine and therapeutic manufacturing represents a distinct commercial opportunity. Cornell's $0.50/dose benchmark at ambient temperature storage, combined with ETEC vaccine immunogenicity data in mice, provides a translational proof of concept relevant to pandemic preparedness, low-income country access, and point-of-care manufacturing programs. The NIH has highlighted decentralized manufacturing as a pandemic preparedness priority.
Cell-Free Protein Synthesis — key questions answered
Cell-free protein synthesis (CFPS) decouples protein production from cellular viability constraints by using cell lysates or reconstituted components to drive coupled transcription–translation in vitro, entirely outside living cells. Conventional cell-based production of biologics — monoclonal antibodies, cytokines, ADCs — is time-consuming, capital-intensive, and dependent on maintaining full cellular viability, which introduces variability and limits flexibility. CFPS removes these constraints.
Sutro Biopharma's 2023 patent (IL jurisdiction) claims large-scale CFPS antibody production at 10–25,000 L reaction volumes using bacterial extracts, with the key innovation of expressing heavy chain (HC) separately from light chain (LC) to improve correctly assembled IgG yields. This indicates IND-enabling or commercial-stage manufacturing capability.
Rather than synthesizing proteins ex vivo, engineered mRNA is delivered in vivo to direct the patient's own cellular machinery to produce therapeutic proteins. Moderna (2021) explicitly frames mRNA-encoded antibodies as addressing manufacturing and purification challenges for mAbs. CureVac demonstrated sequence-engineered unmodified mRNA driving physiological EPO responses in pigs (~20 kg), signaling translational feasibility in large animals. mRNA-in vivo versus CFPS-ex vivo is not binary — drug developers should evaluate which protein targets are better served by each approach.
Cornell University (2022) reports lyophilized CFPS systems producing conjugate vaccines at approximately $0.50/dose (room temperature storage for 4 weeks) or approximately $1.00/dose (50°C, 4 weeks), generating bactericidal antibodies against ETEC O78 in immunized mice.
Goethe University Frankfurt (2022) reports a CFPS pipeline combined with deep learning to design and screen 500 de novo AMP candidates, identifying 30 functional AMPs including 6 with broad-spectrum activity against multidrug-resistant pathogens. This constitutes the clearest example of AI-augmented cell-free drug discovery in the dataset. CFPS is being positioned as the experimental layer in AI-driven drug discovery pipelines, collapsing the design-build-test cycle.
A techno-economic assessment by Imperial College's process systems group identifies that mAb production via CHO-CFPS requires significant yield increases to match conventional CHO manufacturing economics. Eukaryotic CFPS remains a yield-limited bottleneck, representing a high-value technical gap for R&D investment, particularly for glycoprotein targets requiring eukaryotic post-translational modifications.
Still have questions? Let PatSnap Eureka search the patent and literature database for you.
Ask PatSnap Eureka DirectlyAccelerate Your CFPS and Biologic Manufacturing R&D
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search 200M+ patent and literature records to map the full cell-free protein synthesis landscape.
References
- Microscale to Manufacturing Scale-up of Cell-Free Cytokine Production — A New Approach for Shortening Protein Production Development Timelines. Sutro Biopharma, Inc., 2011.
- Development of an E. coli Strain for Cell-Free ADC Manufacturing. Sutro Biopharma, Inc., 2021.
- Method for Large Scale Production of Antibodies Using a Cell-Free Protein Synthesis System. Sutro Biopharma, Inc., 2023, IL. [Patent]
- Improved Cell-Free RNA and Protein Synthesis System. Harvard Medical School, 2014.
- Dissecting Limiting Factors of the Protein synthesis Using Recombinant Elements (PURE) System. MIT, 2017.
- Cell-Free Protein Synthesis Using S30 Extracts from Escherichia coli RFzero Strains for Efficient Incorporation of Non-Natural Amino Acids into Proteins. RIKEN Center for Biosystems Dynamics Research, 2019.
- Design, Development and Optimization of a Functional Mammalian Cell-Free Protein Synthesis Platform. Imperial College London, 2021.
- Techno-Economic Assessment of Cell-Free Synthesis of Monoclonal Antibodies Using CHO Cell Extracts. Imperial College London, 2020.
- Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances. Genzyme Corporation, 2020, IL. [Patent]
- Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances. Genzyme Corporation, 2022, IL. [Patent]
- Integrated Continuous Bioprocessing: Economic, Operational, and Environmental Feasibility for Clinical and Commercial Antibody Manufacture. University College London, 2017.
- Integrated Continuous Biomanufacturing on Pilot Scale for Acid-Sensitive Monoclonal Antibodies. Lund University, 2022.
- Impact of mRNA Chemistry and Manufacturing Process on Innate Immune Activation. Moderna, Inc., 2020.
- Advancements in mRNA Encoded Antibodies for Passive Immunotherapy. Moderna, Inc., 2021.
- Sequence-Engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. CureVac GmbH, 2015.
- Cell-free Biosynthesis Combined with Deep Learning Accelerates De Novo Development of Antimicrobial Peptides. Goethe University Frankfurt, 2022.
- A Low-Cost, Thermostable, Cell-Free Protein Synthesis Platform for On Demand Production of Conjugate Vaccines. Cornell University, 2022.
- World Health Organization (WHO) — Antimicrobial Resistance Global Action Plan.
- European Patent Office (EPO) — Biotechnology Patent Landscape Resources.
- National Institutes of Health (NIH) — Pandemic Preparedness and Decentralized Manufacturing Research.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.